Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:38:29.616Z.
Calculation as of: 2026-10-06T16:38:29.616Z.
Quote observation: 2026-10-06T16:35:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4ee4545eb4fe5103374f291c717036760539f0ddea1c9b76c24efb1a2679ece0
PE RATIO
N/A
Market Cap
$957.13M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Odyssey Therapeutics, Inc. (ODTX) | $936.13M | N/A | N/A | N/A | N/A |
| CeriBell, Inc. (CBLL)vs › | $934.48M | N/A | N/A | N/A | N/A |
| MoonLake Immunotherapeutics (MLTX)vs › | $945.88M | N/A | N/A | N/A | N/A |
| Kura Oncology, Inc. (KURA)vs › | $950.77M | N/A | N/A | N/A | N/A |
| HealthStream, Inc. (HSTM)vs › | $916.63M | 43.86 | 37.03 | 45.62 | 62.08 |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $957.13M | N/A | N/A | N/A | N/A |
| Bioventus Inc. (BVS)vs › | $901.39M | 17.27 | 40.25 | 40.25 | 34.02 |
| Arbutus Biopharma Corp (ABUS)vs › | $889.91M | 5.77 | 5.80 | 5.80 | 5.80 |
| Aktis Oncology, Inc. (AKTS)vs › | $981.04M | N/A | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $984.60M | 71.25 | 118.14 | 119.36 | 99.91 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$19.49
Forward EPS (Est.)
$-5.89
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
